Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Diamond

Showing results (291-300 of 344) with videos related to

Pageof 35
Sort By:
Frontiers in Oncology|May 31, 2017
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerAnastasia A Ionkina, John J Tentler, Jihye Kim, et al.
Breast Cancer Research : BCR|March 1, 2024
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisStephen G Smoots, Anna R Schreiber, Marilyn M Jackson, et al.
Cancers|March 25, 2020
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast CancerTodd M Pitts, Dennis M Simmons, Stacey M Bagby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid TumorsElena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
BMC Genomics|December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancerKaren A Ryall, Jihye Kim, Peter J Klauck, et al.
Molecular Cancer Therapeutics|March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerJohn J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Anti-Cancer Drugs|July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer modelsAnna Capasso, Todd M Pitts, Peter J Klauck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer modelsJennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|February 4, 2016
Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipidIvan R Diamond, Robert C Grant, Paul B Pencharz, et al.
Pageof 35

Showing results (291-300 of 344) with videos related to

Sort By:
Pageof 35
Frontiers in Oncology|May 31, 2017
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerAnastasia A Ionkina, John J Tentler, Jihye Kim, et al.
Breast Cancer Research : BCR|March 1, 2024
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisStephen G Smoots, Anna R Schreiber, Marilyn M Jackson, et al.
Cancers|March 25, 2020
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast CancerTodd M Pitts, Dennis M Simmons, Stacey M Bagby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid TumorsElena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
BMC Genomics|December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancerKaren A Ryall, Jihye Kim, Peter J Klauck, et al.
Molecular Cancer Therapeutics|March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerJohn J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Anti-Cancer Drugs|July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer modelsAnna Capasso, Todd M Pitts, Peter J Klauck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer modelsJennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|February 4, 2016
Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipidIvan R Diamond, Robert C Grant, Paul B Pencharz, et al.
Pageof 35